DP化療方案聯(lián)合康萊特注射液對(duì)肺腺癌患者免疫功能及血管新生指標(biāo)的影響
打開(kāi)文本圖片集
摘 要 目的：探討肺腺癌患者采用多西他賽+順鉑（DP）化療方案聯(lián)合康萊特注射液治療的效果。方法：將92例肺腺癌患者隨機(jī)分為對(duì)照組和觀察組，各46例。對(duì)照組實(shí)施DP化療，觀察組在此基礎(chǔ)上加用康萊特注射液治療，均治療2個(gè)周期，比較兩組治療效果、免疫功能、血管新生指標(biāo)及不良反應(yīng)。結(jié)果：治療后，觀察組疾病控制率，CD3+、CD4+比例和CD4+/CD8+比值高于對(duì)照組；CD8+比例，血管內(nèi)皮生長(zhǎng)因子A、堿性成纖維細(xì)胞生長(zhǎng)因子水平和不良反應(yīng)發(fā)生率低于對(duì)照組（P
關(guān)鍵詞 肺腺癌 DP化療方案 免疫功能 血管新生指標(biāo) 不良反應(yīng)
中圖分類號(hào)：R286； R734.2 文獻(xiàn)標(biāo)志碼：A 文章編號(hào)：1006-1533（2024）17-0036-04
引用本文 陳秀梅， 黃海福. DP化療方案聯(lián)合康萊特注射液對(duì)肺腺癌患者免疫功能及血管新生指標(biāo)的影響[J]. 上海醫(yī)藥， 2024， 45（17）： 36-39.
Effects of DP chemotherapy regimen combined with Kanglaite injection on immune function and angiogenesis indexes in patients with lung adenocarcinoma
CHEN Xiumei， HUANG Haifu
[Department of Oncology， Shenzhen Hospital （Futian）， Guangzhou University of Traditional Chinese Medicine， Shenzhen 518000， China]
ABSTRACT Objective： To investigate the effect of docetaxel plus cisplatin （DP） chemotherapy regimen combined with Kanglaite injection in the treatment of patients with lung adenocarcinoma. Methods： Ninety-two patients with lung adenocarcinoma were randomly divided into a control group and an observation group with 46 cases each. The control group was treated with DP chemotherapy， while the observation group was additionally treated with Kanglaite injection， and all the treatments were lasted for two cycles. The treatment effect， immune function， angiogenesis indexes and incidence of adverse reactions were compared between the two groups. Results： After treatment， the disease control rate， CD3+， CD4+ levels， CD4+/CD8+ value were higher and the levels of CD8+， vascular endothelial growth factor A， basic fibroblast growth factor and the incidence of adverse reactions were lower in the observation group than the control group （P
KEY WORDS lung adenocarcinoma； DP chemotherapy regimen； immune function； neovascularization indices； adverse effects
肺腺癌為非小細(xì)胞癌，發(fā)病率較高，經(jīng)胸部X線檢查可見(jiàn)圓形腫塊，腫塊呈較慢生長(zhǎng)，早期可有血性轉(zhuǎn)移，淋巴結(jié)轉(zhuǎn)移較晚，有研究指出，40%的肺部腫瘤為肺腺癌[1]。（剩余4571字）